Incidence and risk factors for invasive fungal infections in allogeneic BMT recipients

被引:190
作者
Jantunen, E
Ruutu, P
Niskanen, L
Volin, L
Parkkali, T
KoukilaKahkola, P
Ruutu, T
机构
[1] UNIV HELSINKI,CENT HOSP,DEPT MED,FIN-00014 HELSINKI,FINLAND
[2] UNIV HELSINKI,CENT HOSP,DEPT LAB,HELSINKI,FINLAND
关键词
invasive fungal infection; BMT; GVHD; risk factors; incidence;
D O I
10.1038/sj.bmt.1700737
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
In order to analyze the incidence and risk factors for invasive fungal infection (IFI) after allogeneic BMT, 142 consecutive adult BMT recipients (131 sibling donors, 11 unrelated donors) transplanted in 1989-1993 were retrospectively analyzed. There were 21 cases with definite or probable IFI (incidence 15%) (Aspergillus, 15; Candida, four; Fusarium, one; Absidia, one), The median time to the diagnosis of IFI was 136 days after BMT (range 6-466 days), Only 14% of the IFIs were found during the neutropenic period post-BMT. Of the pretransplant characteristics, hematological disease (MDS vs other) (P = 0.001) and unrelated donor (P = 0.01) were risk factors for IFI, Acute GVHD grade III-IV (P = 0.03) and extensive chronic GVHD (P = 0.0002) were also found to be significant risk factors, Only three patients with IFI (14%) became long-term survivors, Invasive fungal infections tended to develop late after BMT, were usually caused by Aspergillus sp,, and were strongly associated with GVHD and its treatment, Better prophylaxis and treatment of IFI are needed, More effective prophylaxis for GVHD might decrease the risk of IFI after allogeneic BMT.
引用
收藏
页码:801 / 808
页数:8
相关论文
共 31 条
[1]  
ALANGADEN G, 1994, BONE MARROW TRANSPL, V14, P919
[2]  
[Anonymous], FUNGAL INFECT DIAGNO
[3]  
ATKINSON K, 1990, BONE MARROW TRANSPL, V5, P209
[4]  
DEBOCK R, 1994, BONE MARROW TRANSPL, V14, pS1
[5]  
DEWITTE T, 1990, BRIT J HAEMATOL, V74, P151
[6]   A CONTROLLED TRIAL OF FLUCONAZOLE TO PREVENT FUNGAL-INFECTIONS IN PATIENTS UNDERGOING BONE-MARROW TRANSPLANTATION [J].
GOODMAN, JL ;
WINSTON, DJ ;
GREENFIELD, RA ;
CHANDRASEKAR, PH ;
FOX, B ;
KAIZER, H ;
SHADDUCK, RK ;
SHEA, TC ;
STIFF, P ;
FRIEDMAN, DJ ;
POWDERLY, WG ;
SILBER, JL ;
HOROWITZ, H ;
LICHTIN, A ;
WOLFF, SN ;
MANGAN, KF ;
SILVER, SM ;
WEISDORF, D ;
HO, WG ;
GILBERT, G ;
BUELL, D .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (13) :845-851
[7]   CLINICAL-FEATURES AND ANALYSIS OF RISK-FACTORS FOR INVASIVE CANDIDAL INFECTION AFTER MARROW TRANSPLANTATION [J].
GOODRICH, JM ;
REED, EC ;
MORI, M ;
FISHER, LD ;
SKERRETT, S ;
DANDLIKER, PS ;
KLIS, B ;
COUNTS, GW ;
MEYERS, JD .
JOURNAL OF INFECTIOUS DISEASES, 1991, 164 (04) :731-740
[8]   RISK-FACTORS FOR FUNGAL INFECTION IN PATIENTS WITH MALIGNANT HEMATOLOGIC DISORDERS - IMPLICATIONS FOR EMPIRICAL THERAPY AND PROPHYLAXIS [J].
GUIOT, HFL ;
FIBBE, WE ;
VANTWOUT, JW .
CLINICAL INFECTIOUS DISEASES, 1994, 18 (04) :525-532
[9]   LOW INCIDENCE OF INVASIVE FUNGAL-INFECTIONS AFTER BONE-MARROW TRANSPLANTATION IN PATIENTS RECEIVING AMPHOTERICIN-B INHALATIONS DURING NEUTROPENIA [J].
HERTENSTEIN, B ;
STEFANIC, M ;
NOVOTNY, J ;
KERN, WV ;
BUNJES, D ;
HEIMPEL, H ;
SCHMEISER, T ;
WIESNETH, M ;
ARNOLD, R .
ANNALS OF HEMATOLOGY, 1994, 68 (01) :21-26
[10]  
HOYLE C, 1994, BONE MARROW TRANSPL, V14, P247